Literature DB >> 18326920

Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature.

Giuseppe Garcea1, Ashley R Dennison, Clare J Pattenden, Christopher P Neal, Christopher D Sutton, David P Berry.   

Abstract

CONTEXT: Patients with resectable pancreatic cancer comprise a small subgroup of the overall population with the disease from around 15 to 20%, with nearly all patients dying from their disease within 7 years of surgery. In the light of such bleak statistics, data regarding what factors may influence outcome, following attempted curative resection is essential in order to optimise the treatment options for patients.
METHODS: This review analysed all English-language publications using PubMed and Web of Science databases for studies detailing outcomes following resection for pancreatic ductal adenocarcinoma from 1980 to the present day. MAIN OUTCOME MEASURES: The data examined from papers were post-operative mortality rates, median survival, yearly survival rates and other factors which may have influenced long-term survival; such as patient demographics, operative details and tumour characteristics (such as example tumour size, lymph node metastases and tumour differentiation).
RESULTS: There has been significant improvement in post-operative mortality over the last decades with a modest improvement in long-term survival. With the exception of post-operative blood transfusion, tumour characteristics remain the only significant features influencing survival after pancreatic cancer surgery. Favourable prognostic factors include tumour size less than 2 cm, negative resection margin, lymph node negative tumours, well-differentiated tumours and absence of perineural or blood vessel invasion.
CONCLUSION: In light of these data, it could be reasoned that tumour size, on cross-sectional imaging, might be employed as means of selecting the most appropriate candidates for surgery, in cases where the risks of resection are high.

Entities:  

Mesh:

Year:  2008        PMID: 18326920

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  94 in total

1.  Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.

Authors:  Daisuke Hashimoto; Kota Arima; Shigeki Nakagawa; Yuji Negoro; Toshihiko Hirata; Masahiko Hirota; Masafumi Inomata; Kengo Fukuzawa; Takefumi Ohga; Hiroshi Saeki; Eiji Oki; Yo-Ichi Yamashita; Akira Chikamoto; Hideo Baba; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2018-12-04       Impact factor: 7.527

Review 2.  Perineural invasion and associated pain in pancreatic cancer.

Authors:  Aditi A Bapat; Galen Hostetter; Daniel D Von Hoff; Haiyong Han
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.

Authors:  Deyali Chatterjee; Asif Rashid; Hua Wang; Matthew H Katz; Robert A Wolff; Gauri R Varadhachary; Jeffrey E Lee; Peter W Pisters; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

4.  Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Hua Wang; Alina C Iuga; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Peter W Pisters; Christopher H Crane; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2012-03       Impact factor: 6.394

Review 5.  Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma.

Authors:  Daneng Li; Eileen M O'Reilly
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

6.  Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Mechteld C de Jong; Fuyu Li; John L Cameron; Christopher L Wolfgang; Barish H Edil; Joseph M Herman; Michael A Choti; Frederick Eckhauser; Kenzo Hirose; Richard D Schulick; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2011-01-31       Impact factor: 3.454

7.  Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience.

Authors:  Niloufar Dusch; Christel Weiss; Philip Ströbel; Peter Kienle; Stefan Post; Marco Niedergethmann
Journal:  J Gastrointest Surg       Date:  2013-11-16       Impact factor: 3.452

8.  Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.

Authors:  Imtiyaz Murtaza; Mohammad Saleem; Vaqar Mustafa Adhami; Bilal Bin Hafeez; Hasan Mukhtar
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

9.  [Pylorus-preserving pancreatic head resection: a new standard for tumors].

Authors:  M Glanemann; M Bahra; P Neuhaus
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

10.  Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head?

Authors:  David Petermann; Nicolas Demartines; Markus Schäfer
Journal:  HPB (Oxford)       Date:  2013-01-29       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.